The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease
Open Access
- 28 September 2011
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 73 (3) , 447-454
Abstract
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Spironolactone has recently been shown to exert beneficial effects on the cardiovascular and renal systems. To date, its use in patients with chronic kidney disease has been limited due to potential risks of hyperkalaemia and declining renal dysfunction.WHAT THIS STUDY ADDS• Non‐diabetic patients with early stage chronic kidney disease (CKD) on concomitant therapy with angiotensin converting enzyme (ACE) inhibition or angiotensin II receptor blockade with a serum potassium of AIM Mineralocorticoid receptor blockade (MRBs) in combination with angiotensin converting enzyme (ACE) inhibitors and angiotensin‐II receptor blockade (ARBs) improve prognostic markers of cardiovascular and renal disease in early stage chronic kidney disease (CKD). Concerns relating to the safety and tolerability of MRBs in CKD may limit their use in a non clinical trial setting.METHODS In the Chronic Renal Impairment in Birmingham II study, 115 patients with non‐diabetic early stage CKD (eGFR 30–89 ml/min/1.73m2) received 25 mg daily of spironolactone for 4 weeks before randomization to continuing treatment or placebo for a further 36 weeks. All patients were on ACE inhibitors and/or ARB therapy. Potassium and renal function were checked at weeks 1, 2, 4, 8, 16, 28 and 40. The incidence of hyperkalaemia, significant renal dysfunction (reduction eGFR ≥25%) and adverse effects was assessed.RESULTS After 40 weeks of treatment the incidence of serious hyperkalaemia (K+≥6.0 mmol/L) was 2. Over follow‐up, three patients experienced significant renal dysfunction but no patients withdrew due to intolerance or side effects. Changes in potassium, eGFR and systolic blood pressure were most apparent in the first 4 eeks.CONCLUSION Spironolactone was well tolerated in selected patients with early stage CKD. Strict monitoring over the first month of treatment followed by standard surveillance as for ACE inhibitors and ARBs is suggested.Keywords
This publication has 26 references indexed in Scilit:
- Spironolactone use and renal toxicity: population based longitudinal analysisBMJ, 2010
- Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation StudyNew England Journal of Medicine, 2004
- British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summaryBMJ, 2004
- Effects of Eplerenone, Enalapril, and Eplerenone/Enalapril in Patients With Essential Hypertension and Left Ventricular HypertrophyCirculation, 2003
- Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactoneNephrology Dialysis Transplantation, 2003
- Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial InfarctionNew England Journal of Medicine, 2003
- Effectiveness of Aldosterone Blockade in Patients With Diabetic NephropathyHypertension, 2003
- Selective Aldosterone Blockade Prevents Angiotensin II/Salt-Induced Vascular Inflammation in the Rat HeartEndocrinology, 2002
- Spironolactone in Addition to ACE Inhibition to Reduce Proteinuria in Patients with Chronic Renal DiseaseNew England Journal of Medicine, 2001
- Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum CreatinineArchives of internal medicine (1960), 2000